Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson's Cell Therapy

About this update from Novo Nordisk A/s Class B

[{"type":"list","items":[{"val":[{"type":"text","content":"Cellular Intelligence has secured global rights to Novo Nordisk's Parkinson's program, a clinical-stage allogeneic cell therapy for Parkinson's disease with FDA Fast Track Designation.","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"Cellular Intelligence will apply its AI foundation model to optimize and scale the program, compressing traditional cell therapy process development and manufacturing timelines, with the goal of removing barriers and reducing costs on the path to commercialization.","length":265,"tagName":"p"}]},{"val":[{"type":"text","content":"Novo Nordisk becomes an equity investor in Cellular Intelligence and is eligible to receive future milestones and royalties.","length":124,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":585,"olType":false},{"type":"text","content":"BOSTON, May 11, 2026 /PRNewswire/ -- Cellular Intelligence today announced that it has acquired global rights to Novo Nordisk's clinical-stage cell therapy program for Parkinson's disease. Cellular Intelligence intends to apply its proprietary AI platform to accelerate clinical development, manufacturing and the path to commercialization. Novo Nordisk will make an equity investment in the company, while remaining eligible for future milestones and royalties.","length":475,"tagName":"p"},{"type":"image","alt":"Cellular Intelligence (PRNewsfoto/Cellular Intelligence)","displaySize":"","headline":null,"caption":"Cellular Intelligence (PRNewsfoto/Cellular Intelligence)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":109,"url":"https://media.zenfs.com/en/prnewswire.com/7cc9878aa5308a406b72521710738236"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/j9lRtCIlydWezBcSp6D3qA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5Mg--/https://media.zenfs.com/en/prnewswire.com/7cc9878aa5308a406b72521710738236","width":400,"height":109},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/EZjgrSyiuUZ19tKxl7AzWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE3NA--/https://media.zenfs.com/en/prnewswire.com/7cc9878aa5308a406b72521710738236","width":400,"height":109}},"href":"https://mma.prnewswire.com/media/2856137/Cellular_Intelligence_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Through this agreement, Cellular Intelligence aim...

More updates from Novo Nordisk A/s Class B